|
John Hodgman joined Immersion’s board of directors on January 31, 2002. In August 2006, he was appointed senior vice president and CFO of InterMune, Inc., a biotechnology company focused on the research, development, and commercialization of innovative therapies in pulmonology and hepatology. From June through October 2005, he was the president and CEO of Aerogen, Inc., during which time he directed the merger with Nektar Corporation. In 1994 he joined Cygnus, Inc., a medical company focused on new and improved glucose monitoring devices, being appointed president and CEO in 1998. He was appointed chairman of the board in 1999, a position he still holds. He also serves as chairman of the board of Inflazyme Pharmaceuticals. Hodgman holds a bachelor’s degree from Brigham Young University and an MBA from the University of Utah. | 